Literature DB >> 23733771

Type I and II endometrial cancers: have they different risk factors?

Veronica Wendy Setiawan1, Hannah P Yang, Malcolm C Pike, Susan E McCann, Herbert Yu, Yong-Bing Xiang, Alicja Wolk, Nicolas Wentzensen, Noel S Weiss, Penelope M Webb, Piet A van den Brandt, Koen van de Vijver, Pamela J Thompson, Brian L Strom, Amanda B Spurdle, Robert A Soslow, Xiao-ou Shu, Catherine Schairer, Carlotta Sacerdote, Thomas E Rohan, Kim Robien, Harvey A Risch, Fulvio Ricceri, Timothy R Rebbeck, Radhai Rastogi, Jennifer Prescott, Silvia Polidoro, Yikyung Park, Sara H Olson, Kirsten B Moysich, Anthony B Miller, Marjorie L McCullough, Rayna K Matsuno, Anthony M Magliocco, Galina Lurie, Lingeng Lu, Jolanta Lissowska, Xiaolin Liang, James V Lacey, Laurence N Kolonel, Brian E Henderson, Susan E Hankinson, Niclas Håkansson, Marc T Goodman, Mia M Gaudet, Montserrat Garcia-Closas, Christine M Friedenreich, Jo L Freudenheim, Jennifer Doherty, Immaculata De Vivo, Kerry S Courneya, Linda S Cook, Chu Chen, James R Cerhan, Hui Cai, Louise A Brinton, Leslie Bernstein, Kristin E Anderson, Hoda Anton-Culver, Leo J Schouten, Pamela L Horn-Ross.   

Abstract

PURPOSE: Endometrial cancers have long been divided into estrogen-dependent type I and the less common clinically aggressive estrogen-independent type II. Little is known about risk factors for type II tumors because most studies lack sufficient cases to study these much less common tumors separately. We examined whether so-called classical endometrial cancer risk factors also influence the risk of type II tumors. PATIENTS AND METHODS: Individual-level data from 10 cohort and 14 case-control studies from the Epidemiology of Endometrial Cancer Consortium were pooled. A total of 14,069 endometrial cancer cases and 35,312 controls were included. We classified endometrioid (n = 7,246), adenocarcinoma not otherwise specified (n = 4,830), and adenocarcinoma with squamous differentiation (n = 777) as type I tumors and serous (n = 508) and mixed cell (n = 346) as type II tumors.
RESULTS: Parity, oral contraceptive use, cigarette smoking, age at menarche, and diabetes were associated with type I and type II tumors to similar extents. Body mass index, however, had a greater effect on type I tumors than on type II tumors: odds ratio (OR) per 2 kg/m(2) increase was 1.20 (95% CI, 1.19 to 1.21) for type I and 1.12 (95% CI, 1.09 to 1.14) for type II tumors (P heterogeneity < .0001). Risk factor patterns for high-grade endometrioid tumors and type II tumors were similar.
CONCLUSION: The results of this pooled analysis suggest that the two endometrial cancer types share many common etiologic factors. The etiology of type II tumors may, therefore, not be completely estrogen independent, as previously believed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23733771      PMCID: PMC3699726          DOI: 10.1200/JCO.2012.48.2596

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  29 in total

1.  Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas.

Authors:  M E Sherman; S Sturgeon; L A Brinton; N Potischman; R J Kurman; M L Berman; R Mortel; L B Twiggs; R J Barrett; G D Wilbanks
Journal:  Mod Pathol       Date:  1997-10       Impact factor: 7.842

2.  Cigarette smoke increases progesterone receptor and homeobox A10 expression in human endometrium and endometrial cells: a potential role in the decreased prevalence of endometrial pathology in smokers.

Authors:  Yuping Zhou; Elisa M Jorgensen; Ye Gan; Hugh S Taylor
Journal:  Biol Reprod       Date:  2011-02-16       Impact factor: 4.285

3.  Dietary and supplemental intake of one-carbon nutrients and the risk of type I and type II endometrial cancer: a prospective cohort study.

Authors:  S Uccella; A Mariani; A H Wang; R A Vierkant; K Robien; K E Anderson; J R Cerhan
Journal:  Ann Oncol       Date:  2011-02-15       Impact factor: 32.976

4.  Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?

Authors:  Teresa Alvarez; Ezra Miller; Linda Duska; Esther Oliva
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

5.  Smoking and the risk of endometrial cancer: results from the Nurses' Health Study.

Authors:  Akila N Viswanathan; Diane Feskanich; Immaculata De Vivo; David J Hunter; Robert L Barbieri; Bernard Rosner; Graham A Colditz; Susan E Hankinson
Journal:  Int J Cancer       Date:  2005-05-10       Impact factor: 7.396

Review 6.  Obesity and cancer.

Authors:  Eugenia E Calle; Michael J Thun
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

7.  Two pathogenetic types of endometrial carcinoma.

Authors:  J V Bokhman
Journal:  Gynecol Oncol       Date:  1983-02       Impact factor: 5.482

8.  A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.

Authors:  J E Nestler; L P Powers; D W Matt; K A Steingold; S R Plymate; R S Rittmaster; J N Clore; W G Blackard
Journal:  J Clin Endocrinol Metab       Date:  1991-01       Impact factor: 5.958

9.  Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study.

Authors:  Hannah P Yang; Nicolas Wentzensen; Britton Trabert; Gretchen L Gierach; Ashley S Felix; Marc J Gunter; Albert Hollenbeck; Yikyung Park; Mark E Sherman; Louise A Brinton
Journal:  Am J Epidemiol       Date:  2012-11-21       Impact factor: 4.897

10.  The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk.

Authors:  T J Key; M C Pike
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

View more
  215 in total

1.  Symposium on advances in endometrial cancer epidemiology and biology.

Authors:  Sara H Olson; Immaculata De Vivo; Veronica W Setiawan; Karen H Lu
Journal:  Gynecol Oncol       Date:  2015-07-29       Impact factor: 5.482

Review 2.  Pathophysiology of heavy menstrual bleeding.

Authors:  Dharani K Hapangama; Judith N Bulmer
Journal:  Womens Health (Lond)       Date:  2015-12-23

3.  Endometrial cancer in morbidly obese women: do racial disparities affect surgical or survival outcomes?

Authors:  M L Cote; J J Ruterbusch; Q Ahmed; S Bandyopadhyay; B Alosh; E Abdulfatah; S Seward; R Morris; R Ali-Fehmi
Journal:  Gynecol Oncol       Date:  2014-04       Impact factor: 5.482

4.  Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells.

Authors:  Joshua Kilgore; Amanda L Jackson; Leslie H Clark; Hui Guo; Lu Zhang; Hannah M Jones; Timothy P Gilliam; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

5.  Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis.

Authors:  Amy S Joehlin-Price; Julie A Stephens; Jianying Zhang; Floor J Backes; David E Cohn; Adrian A Suarez
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-18       Impact factor: 4.254

6.  Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.

Authors:  Yakir Segev; Barry Rosen; Jan Lubinski; Jacek Gronwald; Henry T Lynch; Pal Moller; Charmaine Kim-Sing; Parviz Ghadirian; Beth Karlan; Charis Eng; Dawna Gilchrist; Susan L Neuhausen; Andrea Eisen; Eitan Friedman; David Euhus; Sun Ping; Steven A Narod
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

7.  MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma.

Authors:  Ying Liu; Haiyan Li; Congying Zhao; Hanbing Jia
Journal:  Mol Cell Biochem       Date:  2018-02-05       Impact factor: 3.396

8.  Cardiovascular disease mortality among women with endometrial cancer in the Iowa Women's Health Study.

Authors:  Ashley S Felix; Cindy K Blair; Amy Lehman; Julie K Bower; Subha V Raman; DeAnn Lazovich; David E Cohn; Anna E Prizment
Journal:  Cancer Causes Control       Date:  2017-09-01       Impact factor: 2.506

9.  Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women.

Authors:  Louise A Brinton; Britton Trabert; Garnet L Anderson; Roni T Falk; Ashley S Felix; Barbara J Fuhrman; Margery L Gass; Lewis H Kuller; Ruth M Pfeiffer; Thomas E Rohan; Howard D Strickler; Xia Xu; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-12       Impact factor: 4.254

Review 10.  Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment.

Authors:  Seong Lin Teoh; Srijit Das
Journal:  Tumour Biol       Date:  2016-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.